corticosteroids, and thyroid hormones (10 ) . The expression of ADM messenger RNA (ADM-mRNA) is inducible by shear stress, stretch, hypoxia, and oxidative stress in vascular smooth muscle cells and cardiac myocytes (11) (12) (13) . ADM mediates protective effects for the myocardium by arterial and venous vasodilation, with a decrease of cardiac pre-and afterload and a reduction of total peripheral resistance (14, 15 ) . The characteristic intensive, long-lasting hypotension is dose-dependent in humans, rats, rabbits, dogs, cats, and sheep (10 ) . ADM exerts a protective effect against cardiac hypertrophy and fibrosis in ADM-knockout mice, protects against vascular response to injury, and attenuates the development of left ventricular remodeling and myocardial fibrosis in rats (16, 17 ) . Further properties of ADM include the increase of cardiac contractility and diuresis.
The reliable quantification of ADM is hindered by the immediate binding to its receptors (18 ) , the existence of a binding protein (19 ) , a short half-life (20 ) , and technical difficulties (21 ) . The identification of midregional proadrenomedullin (MR-proADM) has overcome these problems because it is a stable peptide possibly reflecting the concentration of ADM, is theoretically secreted in amounts equimolar to those of ADM, and most likely does not have any physiological effects that might explain its apparent stability (18, 22 ) . Although its detailed pathological role has not been fully explored, increased plasma concentrations of MR-proADM have been related to cardiac dysfunction, systemic inflammatory status, prevalent type 2 diabetes, and renal failure (22) (23) (24) .
Prospectively, plasma MR-proADM concentrations predict adverse outcome in patients in the recovery phase of myocardial infarction and appear to add information beyond the strong predictor N-terminal pro-B-type natriuretic peptide (NT-proBNP) (25 ) . To date, MR-proADM has been investigated in the setting of myocardial infarction only, but not in the range of clinically apparent coronary artery disease (CAD) from stable angina pectoris (SAP) to acute coronary syndrome (ACS). In this work, we evaluated the predictive value of the stable precursor peptide MR-proADM for future cardiovascular events in a large cohort of patients representing the range of symptomatic CAD. We especially aimed to investigate whether measurement of plasma MR-proADM added prognostic information beyond that obtained from comprehensive classic risk models according to the clinical presentation.
METHODS

STUDY POPULATION
Between June 1999 and February 2004, patients with documented CAD referred to the Department of Medicine II of the Johannes Gutenberg-University (Mainz, Germany) and the Department of Medicine of the German Federal Armed Forces Central Hospital (Koblenz, Germany) were enrolled in the AtheroGene study registry. Patients who had either SAP or ACS were included in the present analysis. The study cohort consisted of 2240 patients, 885 with ACS and 1355 with symptoms of SAP. The group of patients with ACS comprised 435 individuals with unstable angina pectoris, 140 with STsegment elevation myocardial infarction (STEMI), 298 with non-STEMI (NSTEMI), and 12 with a nondefinable type of myocardial infarction. Coronary angiography was performed in all patients. The study design has been described (26 ) .
Exclusion criteria were evidence of clinically significant hemodynamic valvular heart disease, surgery or trauma within the previous month, known cardiomyopathy, known cancer, febrile conditions, or use of oral anticoagulant therapy in the previous 4 weeks. We considered patients who were receiving dietary treatment or medication for diabetes or whose current fasting blood glucose concentration was Ͼ125 mg/dL (Ͼ6.94 mmol/L) to have diabetes. Patients who had received antihypertensive treatment or who had received a diagnosis of hypertension were considered to have hypertension. Patients were classified as currently smoking, as having smoked in the past (if they had stopped more than 4 weeks and Ͻ40 years earlier), or as never having smoked (if they had never smoked or had stopped Ն40 years earlier). Among the 2240 patients, 2193 (97.9%) were followed for a mean of 3.6 (1.6) years (maximum 6.9 years). The primary endpoint was a cardiovascular event, defined as a composite endpoint of nonfatal myocardial infarction or cardiovascular death. During the follow-up, we registered 103 cardiovascular deaths, 56 deaths from other causes, and 89 nonfatal myocardial infarctions, corresponding to 192 cardiovascular events. Information about causes of death and clinical events was obtained from the hospital and general-practitioner charts and rated according to predefined criteria by a cardiologist who was not involved in the examinations. The study was approved by the ethics committee of the University of Mainz. Participation was voluntary, and each patient gave written informed consent.
LABORATORY METHODS
Blood was drawn under standardized conditions in serum and EDTA-plasma collection tubes before coronary angiography was performed. We kept blood samples at ambient temperature for 30 min before being centrifuged, and serum or plasma aliquots were removed and stored immediately at Ϫ80°C until measurement.
We detected plasma MR-proADM using a novel commercial assay in the chemiluminescence/coated tube format (MR-proADM LIA, BRAHMS AG) as described (18 ) . The lower limit of detection of the assay is 0.08 nmol/L. The functional assay sensitivity (defined as the lowest concentration detectable with an interassay CV of 20%) is 0.11 nmol/L. The intraassay CVs at 0.5 and 5 nmol/L are 3% and 3.5%, respectively; the interassay CVs at 0.5 and 5 nmol/L are 8.5% and 6.5%. All measurements were done in a blinded fashion in a single batch.
We measured serum NT-proBNP concentration on the ELECSYS 2010 using an electrochemiluminescence immunoassay (ECLIA, Roche Diagnostics). The analytical reporting range is 5-35.000 ng/L. The functional assay sensitivity (defined as the lowest concentration detectable with an interassay CV of 20%) is Ͻ50 ng/L. Intra-and interassay imprecision for the luminescence immunoassay is 0.8%-3.0% and 2.2%-5.8%, respectively. We measured serum C-reactive protein (CRP) on the BNprospec with a highly sensitive, latex particle-enhanced immunoassay (N Cardio Phase hsCRP, Dade Behring). The lower limit of detection of the assay is 1.0 mg/L, the intraassay CV is 2.3%-4.4%, and the interassay CV is 6.5% at 4 mg/L. We measured serum cardiac troponin I (cTnI) using a 1-step sandwich immunoassay (Access ® AccuTnI™ Troponin I Assay, Beckman Coulter) by routine methods; the lower limit of detection for the assay is 0.01 g/L. We measured serum total cholesterol, triglycerides, HDL cholesterol, and creatinine immediately by routine methods; we calculated LDL cholesterol by use of the Friedewald formula. All other measurements were made in plasma and serum that was stored immediately at Ϫ80°C after blood collection and processing.
STATISTICAL ANALYSIS
For descriptive analysis and absolute and relative frequencies of patients, we calculated mean and SD or median and 25th/75th interquartile range for skewed variables for the subgroups of patients with SAP and ACS. We calculated baseline MR-proADM concentrations in stratification according to clinical presentation on admission (SAP, ACS, and overall sample) and for cardiovascular outcome. We compared the concentrations of these groups using the Mann-Whitney U-test.
To test for bivariate correlation of continuous variables to MR-proADM concentrations, we used Spearman's correlation coefficient. For categorical variables, we used the Mann-Whitney U-test to test for a difference between groups. We estimated the cumulative survival curves according to tertiles of MRproADM by the Kaplan-Meier method and compared them with the log-rank test for statistical significance. In all survival analyses, the endpoint was death from cardiovascular causes or nonfatal myocardial infarction. Data from patients who died from other causes were censored at the time of death. We estimated hazard ratios (HRs) for future cardiovascular events according to tertiles, upper vs lower 2 tertiles, 1SD increment of MR-proADM, and MR-proADM as a continuous variable by Cox regression models adjusted for potential confounders. We constructed 3 adjusted models: the first was adjusted for age and sex, the second additionally for 12 further variables of cardiovascular risk prediction (body mass index; hypertension; diabetes; LDL/HDL cholesterol ratio; cigarette smoking; CRP; use of ACE-inhibitor, ␤-blocker, and statin medication; number of coronary vessels affected by CAD; GFR; and history of myocardial infarction), and the third additionally for NT-proBNP concentration. Model 2 with exclusion of CRP was used to compare the HRs of selected biomarkers for the prediction of future cardiovascular events. For cTnI, values above a cutoff of 0.01 g/L were analyzed. All HRs were reported with 95% CIs and 2-sided P values.
To assess the incremental effects of MR-proADM and NT-proBNP in addition to a model with classic risk factors and clinical variables (model 2) for the prediction of a cardiovascular event, we carried out c-statistic analyses with comparison of the c index. The analyses were calculated for a long-term follow-up with the complete observation time and a short-term follow-up of 30 days in the ACS subgroup. There were 129 (5.8%) cardiovascular events within the 2-year follow-up and 22 (2.5%) cardiovascular events within the 30-day short-term follow-up in the ACS subgroup. Using the Youden index, we calculated cutoff values for MR-proADM and NT-proBNP for a long-term follow-up of 2 years. P values are 2-sided; a P value Ͻ0.05 was considered statistically significance. Analyses were performed using R, version 2.12.1 (http:// www.r-project.org).
Results
BASELINE CHARACTERISTICS
The characteristics of the study sample according to status on admission are shown in Table 1 and Supplemental Table 1 , which accompanies the online version of this article at http://www.clinchem.org/content/ vol58/issue1.
MR-proADM AND CARDIOVASCULAR RISK FACTORS
In general, all correlations (Tables 2 and 3) showed concordant trends in both the SAP and ACS groups. MR-proADM concentrations were higher in all subgroups with ACS, generally higher in women, and higher in patients with hypertension and multivessel disease ( Table 2) . MR-proADM concentrations were higher in diabetic patients taking oral antidiabetic agents or insulin. In contrast to other risk factors, MRproADM concentrations were lower in current smokers compared to nonsmokers or those having formerly smoked (Table 2) .
For continuous variables (Table 3) MR-proADM showed, concordantly in both groups, the highest correlations with age, NT-proBNP, and GFR, calculated by the sex-specific Cockcroft formulas. Weaker associations were found with CRP and creatinine in both groups. Body mass index correlated weakly in patients with SAP (r ϭ 0.22) and glucose concentrations in those with ACS (r ϭ 0.24). In those presenting with ACS, MR-proADM was weakly correlated with the biomarkers of cardiac ischemia [myoglobin r ϭ 0.38, creatine kinase (CK)-MB r ϭ 0.22, and troponin I r ϭ 0.22].
MR-proADM AND FUTURE CARDIOVASCULAR RISK
Overall, patients who later suffered from cardiovascular events, defined as cardiovascular death or nonfatal myocardial infarction, had significantly higher MRproADM concentrations at baseline than those without event during follow-up (0.65 vs 0.54, P Ͻ 0.0001). Interestingly, individuals presenting with ACS revealed only slightly, but significantly, higher baseline MRproADM concentrations than those presenting with SAP (0.55 vs 0.53, P ϭ 0.006), whereas baseline NTproBNP concentrations showed a strong difference between the groups (0.42 vs 0.17, P Ͻ 0.0001) ( Table 1) . Fig. 1 and online Supplemental Fig. 1 display MRproADM and log(NT-proBNP) concentrations in patients presenting with SAP and ACS stratified according to the primary endpoint. In both the SAP and ACS subgroups, MR-proADM and log(NT-proBNP) were significantly increased in those individuals who later suffered cardiovascular events. As expected in cohorts of secondary prevention, the strongest clinical predictors were multivessel disease (1.44, 95% CI 1.19 -1.73; P Ͻ 0.0001) and ejection fraction (HR per 1 SD increment 0.97, 95% CI 0.96 -0.98; P Ͻ 0.0001). The strongest risk factor of traditional risk factors was diabetes (HR 1.32; 95% CI 1.17-1.49; P Ͻ 0.0001).
To evaluate effect over time, we performed Kaplan-Meier analyses and applied a series of Cox regression models introducing MR-proADM as a continuous and categorical variable. Kaplan-Meier survival curves for cardiovascular event-free survival according to tertiles of MR-proADM are shown in Fig. 2 . In both subgroups, the highest tertile showed significantly lower event-free survival.
SAP patients had a 1.5-fold increase (95% CI 1.2-1.9; P Ͻ 0.0001) in future cardiovascular risk by increment of 1SD of MR-proADM in a fully adjusted model accounting for most potential confounders (Table 4) . This association remained independent even after adjustment for the strong predictor NT-proBNP. Similar results were obtained in individuals presenting with ACS: 1SD increment of MR-proADM was related to a 1.5-fold increase (95% CI 1.2-1.9; P Ͻ 0.0022) in risk of a future cardiovascular event in the fully adjusted model. The association between MR-proADM and cardiovascular risk was independent in the overall sample regardless of whether analyzed as continuous variable or categorical variable divided into tertiles (Table 4) .
To evaluate the predictive value of MR-proADM in context with established biomarkers, we compared adjusted HRs for future cardiovascular events per increment of 1SD between MR-proADM, NT-proBNP, cTnI, and CRP (online Supplemental Table 2 ). In both subgroups, MR-proADM was the strongest predictor of incident cardiovascular events: 1-increment SD was associated with a 1.62-fold (95% CI 1.35-1.95; P Ͻ 0.0001) increase in risk in SAP and 1.60-fold (95% CI 1.34 -1.90; P Ͻ 0.0001) in ACS patients.
SURVIVAL ANALYSIS
The variables introduced into model 2 of the Cox regression analysis were included in a basic model for analyses of the c-statistics. Table 5 shows the comparison of the basic model against models additionally including MRproADM, NT-proBNP, or both biomarkers.
In the short-term follow-up of 30 days in patients with ACS, inclusion of MR-proADM to the basic model revealed a c-index comparable to that of inclusion of NT-proBNP [area under the curve (AUC) basic model ϩ NT-proBNP 0.76 vs basic model ϩ MRproADM 0.77]. Inclusion of both markers to the basic model did not further increase the AUC. In a long-term follow-up with the complete observation period [median follow-up time 3.6 (1.6) years], this trend persisted in the ACS and SAP subgroups as well as the overall study sample. In both the SAP and ACS subgroups, simultaneous inclusion of both markers to the basic model also did not substantially improve AUC compared to inclusion of a single marker. ROC curve analysis with determination of the Youden index for a long-term follow-up of 2 years revealed a cutoff value of 0.70 nmol/L for MR-proADM and of 728 ng/L for NT-proBNP.
Discussion
In this prospective cohort of patients with documented CAD and typical characteristics for a population of secondary prevention (27 ) , baseline MR-proADM concentrations were independently associated with future cardiovascular events in patients presenting with SAP and those presenting with ACS. In both groups, MRproADM added information beyond that obtained from classic risk models, essentially equal to that of NT-proBNP. Inclusion of both biomarkers did not provide further prognostic information.
Besides renin, aldosterone, catecholamines (epinephrine and norepinephrine), and brain and atrial natriuretic peptide, ADM is 1 of the cardiovascular peptides most commonly involved in the neurohumoral activation of the cardiovascular system (28 ) . In a clinical setting, ADM concentrations are increased in congestive heart failure (7, 8 ) , acute myocardial infarction (7 ), hypertension (29 ) , chronic renal failure (30 ), chronic glomerulonephritis (31 ) , and sepsis (32 ) .
An increasing number of biomarkers have been proposed to identify patients at high risk for future cardiovascular events in secondary prevention (33) (34) (35) . Among those biomarkers, B-type natriuretic peptide or its inactive proform NT-proBNP appear as the strongest risk predictors, adding information to that obtained from classic risk factors (27, 33, 36 ) . A first study targeting ADM in smaller-sized populations raised the hypothesis that ADM might be a predictor of prognosis of similar strength to NT-proBNP in patients with acute myocardial infarction (28 ) . In secondary prevention, increased ADM concentrations were also associated with left ventricular ejection fraction in patients with myocardial infarction (37 ) and an independent predictor of mortality and heart failure in patients with established ischemic left ventricular dysfunction (38 ) . However, ADM itself is unstable and has a short half-life, which compromises its use for potential clinical application. Determination of the stable propeptide MR-proADM allows more reliable measurements.
The present data show the predictive value of MR-proADM across the entire spectrum of symptomatic CAD. Overall, MR-proADM added information for cardiovascular risk stratification. In SAP patients, MR-proADM improved models of cardiovascular risk prediction similar to NT-proBNP. In ACS patients, the determination of MR-proADM associated with future risk for both short-term follow-up of 30 days and long-term follow-up of 2 years. The comparison with other biomarkers of cardiovascular event prediction highlighted the potential clinical utility of MR-proADM. Besides age and glomerular filtration, the highest correlation was to NT-proBNP, which underlines the common, equal directed involvement of both peptides in the neurohumoral activation (14, 15, 28 ) . As reported before in patients with CAD, MRproADM concentrations are higher in women. However, in previous studies with groups of healthy individuals (18, 23, 28 ) and in septic patients (24 ) , no sex difference was observed. Interestingly, our data showed that MR-proADM concentrations were lower in current smokers compared to nonsmokers or those having formerly smoked. This is in line with earlier data, where the fraction of smokers declined with increasing MRproADM quartiles (25 ) . With adrenomedullin being myocardial-protective and having multiple cardioprotective effects (28 ) , it is possible that the beneficial compensatory upregulation is attenuated in smokers. This is supported by the fact that MR-proADM concentrations differed between patients with SAP and those with ACS in former smokers and even more strongly in nonsmokers. In current smokers, however, concentrations did not differ and were overall lower. Table 4 ) on the c index for the prediction of a cardiovascular event in the follow-up for patients with SAP, ACS, and the overall study sample [median follow-up time, 3.6 (1.6) years; maximum 6.9].
The correlation of MR-proADM with the biomarkers of cardiac ischemia in the subgroup of persons with ACS was expected, since an association to acute myocardial infarction has been reported for ADM (39, 40 ) and also for MR-proADM in the Leicester Acute Myocardial Infarction (LAMP) study (25 ) . The patients investigated in the LAMP study were in the recovery phase of acute myocardial infarction, 3-5 days after the event. MR-proADM appeared to be a powerful predictor of adverse outcome, especially in those individuals with increased NT-proBNP.
From a clinical perspective, determination of baseline MR-proADM concentration might add information in secondary prevention models. For a broader understanding of this biomarker, future studies are needed to clarify whether CAD treatment based on statin, beta-blocker, and angiotensin (ACE) inhibition affects MR-proADM concentrations. Reduced MRproADM concentrations would reflect the reduced risk by medical intervention. Furthermore, use of population-based prospective study samples would illustrate whether determination of MR-proADM improves risk models to calculate cardiovascular risk in the general population and primary prevention.
Several limitations merit consideration. We performed only baseline MR-proADM measurement and cannot account for the variability of the peptide during the course of the study or the relation of this variability to myocardial injury. The time between the onset of symptoms and blood sampling was not accounted for, but owing to the large sample size was presumably equally distributed between the groups with and without event in the follow-up period. The measurement of all biomarkers was conducted on samples that were initially stored frozen; however, the stability of MRproADM and the identical treatment of all samples should minimize effects on the validity of our results. The evaluation of diagnoses and events was performed according to predefined criteria by 1 reviewer only; 2 reviewers might have improved data quality. BNP was included in the Cox models as a surrogate for cardiac function left ventricular ejection fraction, history of heart failure, and history of percutaneous coronary intervention/coronary artery bypass graft surgery were included, since these measures were available in only part of the cohort, were not available, or did not improve the model.
In conclusion, our data indicate that MRproADM is an independent predictor, comparable to NT-proBNP, of future cardiovascular events in the setting of CAD. Future clinical investigations are needed to clarify whether determination of MR-proADM is affected by medical therapy in secondary prevention. Furthermore, the prognostic impact of MR-proADM assessment in primary prevention of cardiovascular disease has to be evaluated in population-based studies.
